Navigation Links
Study finds injectable treatment for blood clots in advanced cancer patients increases
Date:2/14/2012

DENVER The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood clots, use of LMWH is low compared to another commonly used anticoagulant, warfarin.

The study was conducted by a team of Kaiser Permanente researchers from Colorado, Oregon, Washington and Northern California, Dana-Farber Cancer Institute and Group Health Research Institute.

Venous thromboembolism, or blood clots, are common and serious complications in cancer patients. Anticoagulation drugs work to prevent additional clots from forming, while the body partially or completely dissolves the initial clot.

The study examined data from electronic health records of four health plans participating in the Cancer Research Network, a consortium of integrated health plans that pool data for research. Patients were identified with advanced breast cancer, colorectal, lung and prostate cancer who received treatment between January 2000 and December 2008 at Group Health Cooperative and Kaiser Permanente regions in Colorado, Northern California and Oregon and Washington.

Over the entire study period, 25 percent of patients received LMWH as a primary treatment for blood clots. A majority of patients, 74 percent overall, received warfarin-based therapy.

"Blood clots are a frequent complication in patients with cancer, so it's essential to understand patterns of care and adherence to guideline recommendations for them," said Dr. Tom Delate, PhD, study lead author. "Current medical literature on this topic is limited, so our findings will add tremendously to this knowledge gap and, hopefully, stimulate discussions on the need for comparative effectiveness research evaluations between blood clot anticoagulation therapies."

A randomized controlled trial in July 2003 demonstrated that LMWH was more effective at preventing recurrent clots than warfarin in patients with cancer. In addition, current clinical guidelines from the American College of Chest Physicians, American Society of Clinical Oncology and National Comprehensive Cancer Network recommend LMWH treatment for cancer-related blood clots.

The study did not determine why warfarin continued to be the preferred anti-coagulation therapy for advanced cancer patients. Warfarin does have a long history of use in treatment of blood clots, and high-quality anticoagulation monitoring services are available in the health plans studied, possibly resulting in a high level of physician comfort with warfarin. In addition, because LMWH requires daily injections, patients may prefer taking warfarin since it is available in tablet form.

According to Dr. Delate, Clinical Pharmacy Research Scientist at Kaiser Permanente Colorado, next steps should be to study why use of LMWH is low compared to warfarin and to compare the effectiveness of LMWH compared with warfarin in patients with advanced cancer.


'/>"/>

Contact: Emily Schwartz
ESchwartz@GolinHarris.com
415-318-4371
Kaiser Permanente
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line ... in Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than ... by government agencies, including NASA. , In 2012, NASA strategically set up 17 ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks ... Amica Insurance is sharing tips to make sure your family and vehicle are ... National Safety Council, there may be 439 deaths and an additional 50,500 serious injuries ...
(Date:5/26/2016)... ... May 26, 2016 , ... Nike Yoga Camps at ... daily practices, arts & crafts, discussions, and games all geared towards enhancing your ... have combined backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
(Date:5/26/2016)... ... May 26, 2016 , ... Workrite ... sales leadership and to further develop their rapidly expanding portfolio of customer and ... with a concentration in Marketing and an M.B.A. with concentration in management from ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 A key trend that ... emergence of new treatments. Cardax, a development stage life ... The therapy is expected to fulfil large unmet medical ... conducting studies to develop new treatments for osteoarthritis. One ... involved in osteoarthritis are being investigated, and early trials ...
(Date:5/26/2016)... Since its commercial introduction in ... life science tool for conducting genetic studies in a ... in its new report that the industry sits on ... by a range of new applications in the clinical ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the Human ...
(Date:5/25/2016)... HILDEN , Deutschland und GERMANTOWN, ... Zusammenarbeit mit Therawis bedient ... Entscheidungen bei Brustkrebs   QIAGEN N.V. ... QIA) gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung ... prädiktiver Assays für die Onkologie eingegangen zu sein. ...
Breaking Medicine Technology: